Myopia Clinical Trial - Safety & Efficacy Study of 0.5%, 0.1% & 0.01%

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to find an optimal dose of atropine for preventing the rapid progression of myopia in children by comparing the efficacy, safety and functional impact of binocular treatment with 0.5%, 0.1% and 0.01% atropine and to develop a treatment regimen for the routine management of childhood myopia.

Clinical Trial Description

A Randomised, Double-Masked Study to Compare The Safety and Efficacy of Bilateral 0.5%, 0.1% & 0.01% Atropine Treatment In Controlling Progression of Myopia In Children

Study Duration and Visit Schedule Total of 5 years with 15 scheduled visits.

1. Phase I: 2 years with 8 scheduled visits

2. Phase II: 3 years with 7 scheduled visits

STUDY DESIGN This study consists of 2 phases, each with a different design. Phase I is a double-masked single-centre clinical trial wherein 400 children aged 6-12 years, with myopia of -2.00 D or worse in each eye, and from whom assent and parental/guardian consent have been obtained, will be randomised to receive 0.5% atropine, 0.1% atropine or 0.01% atropine once nightly in both eyes. Participants will be assigned to treatment in the ratio of 2:2:1, respectively. Each child will receive treatment for a period of 2 years during which they will be reviewed every 4 months.

Phase II is an open-label study wherein all children will continue to be followed-up regularly for changes in their refractive error after stopping atropine treatment. Those children who demonstrate myopia progression of -0.5 D or more, at least on one eye after a minimum of 8 months washout period will restart atropine treatment in both eyes. The appropriate dose will be determined by analysis of the data from Phase I of the study. Treatment will be for a further 2 years and all children, including those not receiving treatment, will be reviewed every 6 months. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Myopia

Clinical Trial Details

NCT number	NCT00371124
Study type	Interventional
Source	Singapore National Eye Centre
Contact
Status	Active, not recruiting
Phase	Phase 2/Phase 3
Start date	March 2006

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04923841` - Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine	N/A
Active, not recruiting	`NCT04080128` - Examination of Myopia Progression and Soft Bifocal Contact Lens Myopia Control	N/A
Active, not recruiting	`NCT05275959` - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)	N/A
Completed	`NCT04604405` - Effects of 650nm Low Energy Light on Human Retina and Choroid Microcirculation	N/A
Recruiting	`NCT05594719` - The Effect of Sun-like Spectrum With Different Spectrum Composition on Retinal Blood Flow	N/A
Completed	`NCT05594732` - The Effects of Different Outdoor Light Exposure Modes on Retinal Blood Flow	N/A
Completed	`NCT04492397` - Comparing The Performance Of Two Different Daily Disposable Lenses (MIKI)	N/A
Completed	`NCT04536571` - Vision Stability and Preference for Soft Toric vs. Soft Spherical Contact Lenses	N/A
Completed	`NCT06046209` - Comparing a Monthly Replacement Lens Versus a Daily Disposable Lens	N/A
Recruiting	`NCT06344572` - Pivotal Study of SAT-001 in Treatment of Pediatric Patient With Myopia	Phase 3
Recruiting	`NCT05611294` - Contralateral Study of Topography Guided LASIK Versus Small Incision Lenticule Extraction	N/A
Completed	`NCT05656885` - Clinical Evaluation of Two Frequent Replacement Soft Spherical Contact Lenses	N/A
Active, not recruiting	`NCT05534022` - Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression.	N/A
Completed	`NCT03934788` - the Clinical Performance of the Oxysoft Daily Disposable Silicone Hydrogel Soft Contact Lens	N/A
Completed	`NCT03701516` - Clinical Evaluation of Etafilcon A Contact Lenses Using a Novel Molding Process 2	N/A
Completed	`NCT05538754` - Post-Market Evaluation of the EVO ICL	N/A
Completed	`NCT03139201` - Clinical Performance of the OxyAqua Daily Disposable Silicone Hydrogel Soft Contact Lens	N/A
Completed	`NCT02555722` - Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear	N/A
Not yet recruiting	`NCT06009458` - Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear	N/A
Recruiting	`NCT05548478` - Corneal Endothelial Cell Injury Induced by Mitomycin-C	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety and Efficacy Study of 0.5%, 0.1% & 0.01% Atropine Treatment to Both Eyes In Treatment of Myopia In Children

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms